IBRX

ImmunityBio Inc. a clinical-stage biotechnology company engages in developing therapies and vaccines that complement harness and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms including antibody cytokine fusion protein N-803 vaccine technologies toll-Like receptor activating adjuvants natural killer cells and damage-associated molecular patterns inducers. The company also develops therapeutic agents which are in Phase II or III clinical trial for the treatment of liquid and solid tumors including bladder pancreatic and lung cancers as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris Inc.; and license agreements with LadRx Corporation GlobeImmune Inc. Access to Advanced Health Institute 3M Innovative Properties Company Sanford Health Shenzhen Beike Biotechnology Co. Ltd. Sorrento Therapeutics Inc. and Viracta Therapeutics Inc. The company is based in San Diego California.